Vnitr Lek 2007, 53(11):1164-1169
Utilisation of Glykogen Phosphorylase BB measurement in the diagnosis of acute coronary syndromes in the event of chest pain
- 1 Interní oddělení nemocnice Šternberk, přednosta prim. MUDr. Bořek Lačňák
- 2 Oddělení laboratorní medicíny nemocnice Šternberk, přednosta doc. MUDr. David Stejskal, Ph.D.
- 3 Ústav humánní farmakologie a toxikologie Farmaceutické fakulty Veterinární a farmaceutická univerzity Brno, vedoucí Ing. Michal Karpíšek
- 4 Centrální laboratoře Šumperské nemocnice, a.s., Šumperk, přednosta Ing. Luděk Šprongl
Introduction:
Glykogen Phosphorylase BB is considered a timely and specific marker of acute coronary syndrome. A kit for measuring Glykogen Phosphorylase BB in routine diagnosis has been released recently.
Objective of the study:
To test the utilisation of Glykogen Phosphorylase BB measurement in the diagnosis of acute coronary syndrome.
Method:
70 patients with suspected acute coronary syndrome were tested. A final diagnosis of acute coronary syndrome/non-coronary difficulties was made according to ESC/ACC/AHA criteria. Measurements of troponin I, myoglobin and GPBB in venous plasma (heparin-lithium) were taken for all probands on admission and two and six hours later.
Results:
Individuals with acute coronary syndrome (n = 52) had significantly higher levels of Glykogen Phosphorylase BB on admission and 2 hours after admission (21.9 vs 6.2; 18.7 vs 5.9 μg/l; p < 0.01). Levels of Glykogen Phosphorylase BB had a greater diagnostic effectiveness for the presence of acute coronary syndrome than levels of troponin I (threshold below ROC curve 0.89 vs. 0.78; 0.87 vs. 0.67). In the first two hours after admission, only levels of Glykogen Phosphorylase BB were included as independent variables in the regression model for the incidence of acute coronary syndrome (p
Keywords: Glykogen Phosphorylase; acute coronary syndromes; non-STEMI; coronary markers
Received: March 18, 2007; Accepted: June 12, 2007; Published: November 1, 2007 Show citation
ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Diagenics. Online: http://www.diagenics.de
- Apple FS, Wu AHB, Mair J et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005; 51: 810-824.
Go to original source...
Go to PubMed...
- Hofmann U, Rabitzsch G, Loster K et al. Immunenzymometric assay for the heart specific glycogen phosphorylase BB in human serum using monoclonal antibodies. Biomed Biochim Acta 1989; 48: 132-136.
- Kemp M, Donova J, Higham H et al. Biochemical markers of myocardial injury. Br J Anaesth 2004; 93: 63-73.
Go to original source...
Go to PubMed...
- Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischaemic myocardial damage. Clin Chim Acta 1998; 272: 79-86.
Go to original source...
Go to PubMed...
- Mair P, Mair J, Krause EG et al. Glycogen phosphorylase isoenzyme BB mass release after coronary artery bypass grafting. Eur J Clin Chem Clin Biochem 1994; 32: 543-547.
Go to original source...
Go to PubMed...
- Mair J, Puschendorf B, Amidy J et al. Release of glycogen phosphorylase in patients with unstable angina and transient ST-T alterationsBr Heart J 1994; 72: 125-127.
Go to original source...
Go to PubMed...
- Peetz D, Post F, Schinzel H et al. Glycogen phosphorylase BB in acute coronary syndromes. Clin Chem Lab Med 2005; 43: 1351-1358.
Go to original source...
Go to PubMed...
- Rabitzsch G, Mair J, Lechleitner P et al. Immunoenzymometric assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995; 41: 966-978.
Go to original source...
- Stejskal D, Lačňák B, Jedelský L et al. The utilisation of glycogen phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. A comparison with results of ELISA. Biomed Papers 2007 (v recenzním řízení).
Go to original source...
- Wu AHB, Apple FS, Gibler WB et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: Recommendations for the Use of Cardiac Markers in Coronary Artery Diseases. Clin Chem 1999; 45: 1104-1121.
Go to original source...
- Achermann M. Doporučení k diagnostice a léčbě nestabilní anginy pectoris - revize 2002. Online: http://www.kardiocz.cz/index.php?&desktop=clanky&action=view&id=86
- Pettila I, Penttila K, Rantanen T. Laboratory diagnosis of patients with acute chest pain. Clin Chem Lab Med 2000; 38: 187-197.
Go to original source...
- Lu Y, Yu HL, Yang S. Relationship between glycogen phosphorylase BB and cardiac ischemic area or infarction area in experimental acute myocardial infarction. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2005; 17: 433.
- Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs 2003; 35: 36-38.
- Ortak M, Holle AK, Lehmann W et al. GPBB - a promising cardiac marker in early detection of acute myocardial infarction. Clin Res Cardiol 2007; 96(Suppl 1): V1917.
- Klabunde RE. Cardiovascular Physiology Concepts. Online: http://www.cvphysiology.com/Blood%20Pressure/BP006.htm
- Albert JS, Thygesen K, Altman E et al. Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36: 959-969.
Go to original source...
Go to PubMed...